This study investigates advanced pancreatic cancer. The purpose of this study is to explore whether adding a low dose of EGFR blocking drugs to the standard chemotherapy regimen is safe and tolerable for patients with this condition.
Researchers will evaluate the safety and effectiveness of the treatment combination. They will monitor long-term outcomes such as overall survival and tumor response to the treatment.
- Who can participate: Adults aged 18 years and older with advanced pancreatic cancer may be eligible. Participants must have a specific performance status and consent to a pre-study biopsy if needed.
- Study details: Participants will receive a combination of chemotherapy and an investigational medication. Some may receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.